Related Experiment Video

Updated: May 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis

Lian Gu1, Qing Chen, Juanjuan Xie

  • 1Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, Guangxi, China.

Die Pharmazie
|January 26, 2013
PubMed

Insights

Telaprevir combined with peginterferon alfa and ribavirin improves viral response and reduces relapse in genotype 1 chronic hepatitis C patients. However, this treatment increases severe adverse events and discontinuation, requiring careful monitoring.

Area of Science:

  • Hepatology and Virology
  • Pharmacology and Drug Development

Background:

  • Chronic hepatitis C (HCV) genotype 1 is a significant global health concern.
  • Current treatment regimens aim to achieve sustained virologic response and prevent relapse.

Purpose of the Study:

  • To evaluate the efficacy and safety of telaprevir in combination therapy for genotype 1 chronic hepatitis C.
  • To assess viral response, relapse rates, and adverse events associated with telaprevir treatment.

Main Methods:

  • A systematic review and meta-analysis of randomized clinical trials.
  • Inclusion criteria: trials comparing telaprevir plus peginterferon alfa and ribavirin versus control in genotype 1 chronic hepatitis C patients.
  • Primary outcomes: sustained virologic response and end-of-treatment virologic response; secondary outcomes: relapse, severe adverse events, and treatment discontinuation.

Main Results:

  • Telaprevir combination therapy significantly improved sustained virologic response, end-of-treatment response, and reduced relapse rates in naive and previously treated patients, with some exceptions.
  • The T12PR12 regimen showed no significant benefit in sustained virologic response or relapse rates for naive patients.
  • A higher incidence of severe adverse events and treatment discontinuation due to adverse events was observed in previously treated patients, but not in naive patients.

Conclusions:

  • Telaprevir in combination with peginterferon alfa and ribavirin is an effective option for genotype 1 chronic hepatitis C, improving viral response and reducing relapse.
  • Careful monitoring is essential due to the potential for severe adverse events.
  • Further randomized clinical trials are needed to confirm treatment effects and elucidate potential adverse events.
Abstract

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...